Pancreatic cancer has long been one of the deadliest cancers, with over 97% of metastatic patients dying within five years. A new oral drug called daraxonrasib has achieved what scientists once considered impossible: neutralizing the KRAS protein mutation that drives more than 90% of pancreatic tumors. Instead of targeting KRAS directly, the drug binds to a helper molecule called cyclophilin A, which then shuts down KRAS signaling. In a Phase 3 clinical trial of 500 patients with advanced pancreatic cancer, daraxonrasib nearly doubled survival rates and reduced the risk of death by 60%. This marks a fundamental shift in how oncologists may approach one of medicine's most resistant cancers.
